Spots Global Cancer Trial Database for pembrolizumab
Every month we try and update this database with for pembrolizumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | NCT05404945 | Classical Hodgk... | Pembrolizumab Doxorubicin Vinblastine Dacarbazine Brentuximab ved... | 60 Years - | University of Virginia | |
| Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) | NCT02564380 | Metastatic Squa... | Pembrolizumab Placebo | 18 Years - | AIO-Studien-gGmbH | |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer | NCT02933944 | Rectal Cancer | TG02-treatment Pembrolizumab | 18 Years - | Targovax ASA | |
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | NCT02563002 | Colorectal Carc... | mFOLFOX6 FOLFIRI pembrolizumab bevacizumab cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) | NCT03898180 | Urothelial Carc... | Pembrolizumab Lenvatinib Placebo for len... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | NCT04198766 | Solid Tumor Non-Small Cell ... Melanoma Head and Neck C... Gastric Cancer Renal Cell Carc... Urothelial Carc... | INBRX-106 - Hex... Pembrolizumab 2... Pembrolizumab 4... | 18 Years - | Inhibrx, Inc. | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | NCT04882241 | Gastric Cancer Gastroesophagea... | Pembrolizumab Placebo Cisplatin Capecitabine 5-fluorouracil Docetaxel Oxaliplatin Leucovorin | 18 Years - | Merck Sharp & Dohme LLC | |
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | NCT04223856 | Urothelial Canc... | Enfortumab vedo... Pembrolizumab Cisplatin Carboplatin Gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | NCT02621398 | Stage II Non-Sm... Stage IIIA Non-... Stage IIIB Non-... | 3-Dimensional C... Carboplatin Intensity-Modul... Laboratory Biom... Paclitaxel Pembrolizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | NCT05789082 | Non-Small Cell ... | Divarasib Pembrolizumab Carboplatin Cisplatin Pemetrexed | 18 Years - | Hoffmann-La Roche | |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | NCT04534205 | Unresectable He... Metastatic Head... Recurrent Head ... | BNT113 Pembrolizumab | 18 Years - | BioNTech SE | |
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT | NCT03435952 | Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... Malignant Neopl... | Pembrolizumab Clostridium Nov... Doxycycline | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma | NCT03519997 | Hepatocellular ... | Pembrolizumab Bavituximab | 18 Years - | University of Texas Southwestern Medical Center | |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | NCT05104567 | Oesophageal Squ... Gastric Cancer Hepatocellular ... Colorectal Canc... Oesophageal Ade... | THOR-707 Pembrolizumab Cetuximab | 18 Years - | Sanofi | |
| Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC | NCT05418660 | Non-small Cell ... | Immunotherapy | 18 Years - | University of Milano Bicocca | |
| A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | NCT06057038 | Malignant Solid... | GEN1042 Pembrolizumab Cisplatin Carboplatin 5-Fluorouracil | 18 Years - | Genmab | |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | NCT04675294 | Head and Neck C... Head and Neck S... | evorpacept pembrolizumab | 18 Years - | ALX Oncology Inc. | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | NCT02954536 | Esophageal Canc... Gastric Cancer | pembrolizumab trastuzumab capecitabine cisplatin Oxaliplatin 5-Fluorouracil | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China | NCT04740996 | Head and Neck S... | Pembrolizumab | 18 Years - | ChineseAMS | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma | NCT03486197 | Urothelial Carc... | Laboratory Biom... Pembrolizumab Radiation Thera... | 18 Years - | University of Washington | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy | NCT03319745 | Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IIIA Blad... Stage IIIB Blad... | Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR | NCT06393374 | Triple-Negative... | Pembrolizumab sac-TMT Capecitabine | 18 Years - | Merck Sharp & Dohme LLC | |
| A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | NCT05967182 | Cholangiocarcin... | Pembrolizumab Gemcitabine Cisplatin | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | NCT04383938 | Bladder Cancer Gastric Cancer Non Small Cell ... NSCLC Urothelial Carc... Advanced Solid ... | APR-246 (eprene... | 18 Years - | Aprea Therapeutics | |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | NCT03425006 | Non Small Cell ... | Itacitinib Pembrolizumab | 18 Years - | University of Pennsylvania | |
| Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement | NCT04645602 | Human Papilloma... Recurrent Respi... | Lenvatinib Pembrolizumab | 18 Years - | Massachusetts General Hospital | |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | NCT02757391 | Colorectal Aden... Metastatic Chol... Metastatic Colo... Metastatic Dige... Metastatic Esop... Metastatic Gast... Metastatic Panc... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Adoptive Immuno... Aldesleukin Cyclophosphamid... Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study | NCT03881111 | Esophageal Neop... | Pembrolizumab Placebo Cisplatin 5-FU | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study | NCT04865289 | Endometrial Neo... | Lenvatinib Pembrolizumab Paclitaxel Carboplatin | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | NCT06422143 | Non-small Cell ... NSCLC | Pembrolizumab sac-TMT | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) | NCT02934503 | Small Cell Lung... | Pembrolizumab Cisplatin Carboplatin Etoposide Radiation thera... | 19 Years - | NYU Langone Health | |
| Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | NCT03367871 | Cervical Cancer | Pembrolizumab Paclitaxel Cisplatin Carboplatin Bevacizumab | 18 Years - | University of Miami | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | NCT02581943 | Recurrent Non-S... Stage IIIB Non-... Stage IV Non-Sm... | Carboplatin Laboratory Biom... Paclitaxel Pembrolizumab Quality-of-Life... | 18 Years - | Wake Forest University Health Sciences | |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | NCT03137771 | Recurrent Non-S... Stage IV Non-Sm... | 3-Dimensional C... Docetaxel Gemcitabine Intensity-Modul... Pemetrexed Diso... Stereotactic Bo... Erlotinib Hydro... Pembrolizumab | 18 Years - | NRG Oncology | |
| Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer | NCT04224740 | Penile Carcinom... | Pembrolizumab Standard of car... | 18 Years - | Latin American Cooperative Oncology Group | |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | NCT03474497 | Non Small Cell ... Metastatic Mela... Metastatic Rena... Head and Neck S... | IL-2 Pembrolizumab Radiotherapy | 18 Years - | University of California, Davis | |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | NCT06225596 | Metastatic Urot... | BT8009 BT8009 BT8009 Pembrolizumab Gemcitabine + c... Avelumab | 18 Years - | BicycleTx Limited | |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | NCT04201873 | Recurrent Gliob... | Dendritic Cell ... Pembrolizumab Placebo Adminis... Poly ICLC | 18 Years - | Jonsson Comprehensive Cancer Center | |
| PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % | NCT04547504 | Non-small-cell ... | Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Brest | |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | NCT04609566 | Melanoma Non-small Cell ... Squamous Cell C... | brentuximab ved... pembrolizumab | 18 Years - | Seagen Inc. | |
| A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | NCT03516981 | Advanced Non-Sm... | Pembrolizumab Favezelimab Lenvatinib Quavonlimab | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD | NCT05578222 | NSCLC With COPD | Pembrolizumab | 18 Years - 75 Years | Tianjin Chest Hospital | |
| A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) | NCT05382325 | Advanced or Met... | MK-1484 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | NCT03414229 | Sarcoma | Epacadostat Pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | NCT05378425 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Locally Advance... | NTX-1088 Pembrolizumab | 18 Years - | Nectin Therapeutics Ltd | |
| PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | NCT06157151 | Cervical Cancer HPV-Related Car... HPV-Related Mal... | PRGN-2009 plus ... Pembrolizumab a... | 18 Years - | Precigen, Inc | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | NCT04510636 | Classical Hodgk... Relapsed Cancer Refractory Canc... | Pembrolizumab Bendamustine Hy... | 18 Years - | University Health Network, Toronto | |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | NCT03126630 | Pleural Maligna... | Anetumab Ravtan... Laboratory Biom... Pembrolizumab Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer | NCT04768686 | Gastric Cancer | FLX475 Pembrolizumab | 18 Years - | Hanmi Pharmaceutical Company Limited | |
| Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | NCT02875067 | Relapsed Hodgki... Relapsed Non-Ho... | Pembrolizumab Lenalidomide | 18 Years - | NYU Langone Health | |
| Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC | NCT06052839 | Recurrent/Metas... | Pembrolizumab Carboplatin Paclitaxel | 18 Years - | University of Pittsburgh | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Study of Pembrolizumab and Olaparib in Bile Duct Cancer | NCT04306367 | Cholangiocarcin... | Pembrolizumab Olaparib | 18 Years - | Georgetown University | |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | NCT02675946 | Solid Tumors GI Cancer | CGX1321 Pembrolizumab encorafenib cetuximab | 18 Years - | Curegenix Inc. | |
| Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | NCT05461235 | PD-1 Antibody DC-Cell NK-Cell Gastrointestina... | Pembrolizumab Nivolumab Sintilimab Toripalimab Camrelizumab Tislelizumab NK-Cell or DC-C... | 18 Years - 70 Years | China Medical University, China | |
| GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | NCT05998447 | Biliary Tract C... | GEN-001 Pembrolizumab mFOLFOX | 19 Years - | Genome & Company | |
| Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | NCT03739138 | Advanced Solid ... | MK-4621 Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | NCT03322566 | Lung Cancer | Pembrolizumab Epacadostat Platinum-based ... Placebo | 18 Years - | Incyte Corporation | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04781088 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Lenvatinib Paclitaxel Pembrolizumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | NCT03150329 | Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran... | Laboratory Biom... Pembrolizumab Vorinostat | 18 Years - | City of Hope Medical Center | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | NCT03666273 | Advanced Solid ... Head and Neck S... | Bapotulimab (BA... Bapotulimab (BA... | 18 Years - | Bayer | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17) | NCT04153565 | Mesothelioma | Pembrolizumab Pemetrexed Cisplatin | 20 Years - | Merck Sharp & Dohme LLC | |
| Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition | NCT03453892 | Metastatic Canc... | Nivolumab Pembrolizumab Radiotherapy Ipilimumab | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | NCT04220892 | High Grade Glio... | Pembrolizumab Pemetrexed Abemaciclib | 18 Years - | Saint John's Cancer Institute | |
| Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | NCT06242834 | B-Cell Non-Hodg... | Biospecimen Col... Computed Tomogr... Echocardiograph... Pembrolizumab Positron Emissi... Tazemetostat | 18 Years - | Northwestern University | |
| First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | NCT03681951 | Neoplasms, Panc... | GSK3145095 Pembrolizumab | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
